

PHARMANUTRA S.P.A. JOINS THE “INTERMONTE VALORE ITALIA INDEX”

The Company has been included among the 100 mid- and small-cap companies that constitute the index, which is part of PMI2Change, Banca Generali’s innovative project presented on July 1, 2026, at Borsa Italiana’s Palazzo Mezzanotte.

Pisa, 2 July 2026 – Pharmanutra (MTA; Ticker PHN), a company specialising in mineral-based nutritional supplements and medical devices for muscles and joints, is proud to announce that it has been selected as one of the 100 companies listed on the Borsa Italiana that constitute the **Intermonte Valore Italia Index**, which is dedicated to SMEs with a market capitalization lower than one billion euros and that are not included in the FTSE MIB.

The Index was created with the aim of highlighting the universe of listed Italian small and medium-sized enterprises, creating a common ground where entrepreneurship, capital markets, and the national economy can come together. It offers a true cross-section of the best expertise in the Italian economy, helping to broaden and diversify investment opportunities compared to traditional indices for both domestic and international investors.

The Index is part of **PMI2Change**, Banca Generali’s innovative project presented on July 1, 2026, at Borsa Italiana’s Palazzo Mezzanotte, which aims to support the growth and competitiveness of Italian entrepreneurs by fostering the development of domestically listed SMEs. The project addresses the issue of limited liquidity and undervaluation of listed SMEs, helping to create the best conditions for a more efficient match between capital and businesses.

The initiative builds on the expertise of Intermonte, a leading Italian player in the sector with over thirty years of experience in financial markets—particularly in SME research, sales & trading, market making, and investment banking—which has been an integral part of the Banca Generali Group since the beginning of 2025.

Building on the Index, Banca Generali, together with Investlinx and Intermonte, has launched a new actively managed, PIR-compliant ETF that will invest primarily in the universe defined by the Index itself. Banca Generali has committed to supporting the launch of the fund with an initial capital raise of 100 million euros in the first few months, with a gradual increase in exposure to reach 500 million euros in the medium term. It is therefore estimated that the initiative could help generate new investment inflows of 1–2 million euros per day, representing over 5% of the Index’s free float.

Pharmanutra S.p.A.

Via Campodavola, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259



Roberto Lacorte, Vice President and CEO of Pharmanutra, commented: *"We are proud to have been selected for the Intermonte Valore Italia Index, a recognition that rewards not only the solidity, transparency, and quality of our growth trajectory, but also the role that Italian small and medium-sized enterprises play in the Country's development. This project places the Italian entrepreneurial and economic fabric back at the center, highlighting companies that successfully combine vision, innovation, and sustainability. Being included in this index reaffirms our commitment to pursuing sustainable growth and creating long-term value for our shareholders and all stakeholders"*

Pharmanutra and the other companies were selected through rigorous technical and financial criteria designed to ensure adequate levels of liquidity, transparency, and investability, including: minimum free float, strong governance standards, analyst coverage, financial sustainability, and debt levels, as well as representativeness within the Index itself.

Pharmanutra S.p.A.

Founded in 2003 in Pisa by Andrea and Roberto Lacorte, Pharmanutra is the holding company of an international Group engaged in the research, development, and commercialization of nutritional supplements, medical devices, and patented raw materials. A leader in iron-based supplements through its Sucrosomial® Technology (SiderAL® and Apportal®), and an emerging player in medical devices for mobility (Cetilar®), the Group internally manages the entire value chain and holds a solid portfolio of patents, brands, and clinical evidence.

Pharmanutra operates in over 80 countries, with subsidiaries in the USA and Spain, and also includes Akern S.r.l. (bioimpedance analysis) and Atletica Cetilar S.r.l. (sports medicine)

pharmanutragroup.com

pharmanutra.it

For further information:

Pharmanutra S.p.A.

Via Campodavola 1 - 56122 Pisa

Tel. +39 050 7846500

Simona Del Re

s.delre@pharmanutra.it

investorrelation@pharmanutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milano

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Pharmanutra S.p.A.

Via Campodavola, 1 - 56122 Pisa | +39 050 7846500

pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it

C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259

